Medrx Co (TSE:4586) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4586 Medrx Co Ltd TSE:4586
64 GF Score
Price 円68.00
GF Value 円70.57
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Medrx Co 5-Year Yield-on-Cost %?

Medrx Co TSE:4586 -1.45% 64 5-Year Yield-on-Cost % is 0.00 as of Aug. 07, 2026. GuruFocus rates TSE:4586 with a GF Score™ of 64/100 and a GF Value™ of 円70.57 (Fairly Valued). The stock has 3 warning signs investors should review. Among 513 Drug Manufacturers companies, Medrx Co ranks worse than 194931.58% on this metric.

Medrx Co's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Medrx Co's 5-Year Yield-on-Cost % or its related term are showing as below:



TSE:4586's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.29
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Medrx Co  (TSE:4586) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Medrx Co 5-Year Yield-on-Cost % Related Terms


TSE:4586 vs ZTS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medrx Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medrx Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medrx Co's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Medrx Co's 5-Year Yield-on-Cost % falls into.


TSE:4586
64GF Score
Medrx Co Ltd TSE:4586
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medrx Co 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Medrx Co is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Medrx Co (TSE:4586) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Medrx Co and its competitors. According to the industry distribution chart, Medrx Co ranks #999999 out of 513 companies in the Drug Manufacturers industry.
Is Medrx Co's 5-Year Yield-on-Cost % too high?
Medrx Co's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Medrx Co ranks #999999 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medrx Co has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medrx Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medrx Co ranks #999999 out of 513 companies for 5-Year Yield-on-Cost %. This places Medrx Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Medrx Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medrx Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medrx Co stock overvalued right now?
Based on GuruFocus' analysis, Medrx Co (TSE:4586) is currently considered Fairly Valued. The stock's GF Value™ is 円70.57, compared to a current price of 円68.00 — trading 3.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Medrx Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Medrx Co (TSE:4586), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medrx Co (TSE:4586) Overvalued in 2026?

Based on GuruFocus' analysis, Medrx Co stock appears to be undervalued. The current stock price of 円68.00 is trading 3.6% below its estimated GF Value™ of 円70.57. GuruFocus considers Medrx Co to be Fairly Valued.

Key valuation signals for TSE:4586:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: 円70.57 vs. price of 円68.00 (3.6% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TSE:4586 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medrx Co Business Description

Address 431-7 Nishiyama, Higashikagawa, Kagawa, JPN, 769-2712
Medrx Co Ltd is a pharmaceutical drug development company founded in January, 2002. The Company engaged in the research and development of pharmaceutical products utilizing the pharmaceutical formulation technology based on ionic liquid transdermal system. The Company develops new pharmaceutical candidates and licenses other companies to produce the pharmaceuticals after clinical trials. Its main products include analgesic patches for anti-inflammatory and pain relief.
64GF Score

Get the complete analysis for TSE:4586

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円68.00
Price
円70.57
GF Value